ClinicalTrials.gg
CompletedNCT00833703CLARINET LTUpdated Aug 22, 2011Results posted

Long Term Safety of Clopidogrel in Neonates/Infants With Systemic to Pulmonary Artery Shunt Palliation

A Phase 3 interventional study of Clopidogrel and placebo in Heart Defects, Congenital, sponsored by Sanofi. Completed at 15 sites in 15 countries. Open to participants aged 12 Months and older. Per ClinicalTrials.gov, last updated 2011-08-22.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
49
Allocation
Randomized
Ages
12 Months and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 356 studies in Heart Defects, Congenital with a site in United States — 66 open to participants now, 87 under way, 4 of them phase 3. Heart Defects, Congenital · United States.

Enrollment
93rd of 184
49 · median 50
Started
2009
with 10 others
Phase 3
19 of 356
2 open now
Registered
80th of 356
by date

Among the 356 studies in Heart Defects, Congenital with a site in United States, this one is the 93rd largest by enrollment of the 184 interventional ones that give a count, is one of 11 that started in 2009, is one of 19 in phase 3, and was the 80th registered.

Heart Defects, Congenital

992 studies on the registry are indexed under Heart Defects, Congenital; 251 are open to participants now.

Browse Heart Defects, Congenital studies →

Open to participants now

66 of the 356 studies in Heart Defects, Congenital with a site in United States are open now. Recruiting first, the newest first:

61 more — sign in →

All 66 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 154 Heart Defects, Congenital studies recruiting now, 67 (44%) set no upper age limit and 79 (51%) stop at 75 or younger; 110 take children under 18; 25 take healthy volunteers.

This study: 12 Months and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 356 studies in Heart Defects, Congenital with a site in United States, or all of them as a file.
02

Study summary

This study is the extension of the CLARINET study [NCT00396877 -EFC5314] in neonates or infants with cyanotic congenital heart disease palliated with a systemic-to-pulmonary artery shunt.

The primary objective was to assess the safety up to 18 months of age of the extended use of Clopidogrel 0.2 mg/kg/day in patients for whom the shunt was still in place at one year of age.

The secondary objective was to assess the efficacy on the occurrence of shunt thrombosis requiring intervention or any death.

Read the detailed description

Patients remained in the treatment group to which they were originally allocated for the CLARINET study and continued blindly their treatment (0.2 mg/kg/day of clopidogrel or placebo) up to the occurrence of shunt thrombosis, next surgical procedure for correction of the congenital heart disease, death, or 18 months of age, whichever came first. The maximum treatment duration were 6 months.

03

Conditions studied

  • Heart Defects, Congenital

Keywords

  • cyanotic congenital heart disease
  • shunt palliation
  • thrombosis
  • clopidogrel
04

Who can participate

Ages eligible
12 Months and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Patients randomized in the CLARINET study,
  • Still receiving the study drug,
  • Palliative systemic-to-pulmonary artery shunt still in place at 1 year of age,
  • Investigator's decision to continue based on his/her judgment of the expected benefit / risk of continuing treatment with study drug,
  • Signed to participate in the long-term safety study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
49 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    0.2 mL/kg/day matching placebo solution once daily.

    Drug: placebo

  • Experimental
    Clopidogrel 0.2 mg/kg/day

    0.2 mL/kg/day Clopidogrel reconstituted solution at 1mg/mL once daily.

    Drug: Clopidogrel

Interventions

  • Form: reconstituted solution using Clopidogrel powder Route: oral or enteric Frequency: once daily Dose: daily dose adjusted for weight

    Also known as: SR25990, Plavix

  • Drugplacebo

    Form: reconstituted solution using matching placebo powder Route: oral or enteric Frequency: once daily Dose: daily dose adjusted for weight

06

What researchers measure

Primary outcomes

  1. Number of Participants With Bleeding Events

    All bleeding events experienced during the study period were collected as for any Adverse Event. The 'on-treatment' period was defined as the period from inclusion in the extension study up to 28 days after treatment discontinuation, and participants who experienced bleeding events during that period were counted.

    Time frame: Up to a maximum of 6 months

  2. Number of Participants According to Bleeding Type/Etiology

    For all reported bleeding events, the type and the etiology of the bleeding event were collected. Participants who experienced bleeding events during the 'on-treatment period' were counted by bleeding type and etiology.

    Time frame: Up to a maximum of 6 months

Secondary outcomes

  1. Number of Participants With Shunt Thrombosis Requiring Intervention or Deaths

    Outcome events, shunt thrombosis requiring intervention or death, experienced during the study period were recorded. Participants were counted excluding the events that occured after the participant's protocol study end (occurrence of shunt thrombosis, next surgical procedure for correction of the congenital heart disease, death, or 18 months of age, whichever came first).

    Time frame: Up to a maximum of 6 months

07

Results

Posted Aug 16, 2011

Participant flow

49 participants were enrolled between January 2009 and January 2010 in 25 sites in 15 countries (7 countries involved in CLARINET study were not selected as the delay in obtaining IRB/IEC and Health Authorities approvals would prevent recruitment and/or no patient would be recruited as the second surgery is always performed before 1 year of age).

Participant flow — Overall Study
MilestonePlaceboClopidogrel 0.2 mg/kg/Day
Started2326
Treated2326
Completed treatment2224
Completed2325
Not completed01
Withdrew: Parent(s)/guardian(s)'s request01

Outcome measures

PrimaryNumber of Participants With Bleeding Events

All bleeding events experienced during the study period were collected as for any Adverse Event. The 'on-treatment' period was defined as the period from inclusion in the extension study up to 28 days after treatment discontinuation, and participants who experienced bleeding events during that period were counted.

Time frame:
Up to a maximum of 6 months
Reported as:
Number · participants
Number of Participants With Bleeding Events
participantsPlaceboClopidogrel 0.2 mg/kg/Day
Any bleeding event02
- Serious00
- Serious with an outcome of death00
- Leading to permanent treatment discontinuation00
SecondaryNumber of Participants With Shunt Thrombosis Requiring Intervention or Deaths

Outcome events, shunt thrombosis requiring intervention or death, experienced during the study period were recorded. Participants were counted excluding the events that occured after the participant's protocol study end (occurrence of shunt thrombosis, next surgical procedure for correction of the congenital heart disease, death, or 18 months of age, whichever came first).

Time frame:
Up to a maximum of 6 months
Reported as:
Number · participants
Number of Participants With Shunt Thrombosis Requiring Intervention or Deaths
participantsPlaceboClopidogrel 0.2 mg/kg/Day
shunt thrombosis requiring intervention00
death10
PrimaryNumber of Participants According to Bleeding Type/Etiology

For all reported bleeding events, the type and the etiology of the bleeding event were collected. Participants who experienced bleeding events during the 'on-treatment period' were counted by bleeding type and etiology.

Time frame:
Up to a maximum of 6 months
Reported as:
Number · participants
Number of Participants According to Bleeding Type/Etiology
participantsPlaceboClopidogrel 0.2 mg/kg/Day
Spontaneous01
Puncture (vascular access site)01

Adverse events

Collected over Up to a maximum of 6 months. All Adverse Events (AE) experienced during the study period were collected regardless of seriousness or relationship to the drug .. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—3/23 (13%)7/23 (30.4%)
Clopidogrel 0.2 mg/kg/Day—6/26 (23.1%)17/26 (65.4%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventPlaceboClopidogrel 0.2 mg/kg/Day
Diaphragmatic paralysisRespiratory, thoracic and mediastinal disorders1/230/26
Pulmonary artery stenosisRespiratory, thoracic and mediastinal disorders1/230/26
Ischaemic strokeNervous system disorders1/230/26
BronchiolitisInfections and infestations0/231/26
Croup infectiousInfections and infestations0/231/26
GastroenteritisInfections and infestations0/231/26
Urinary tract infectionInfections and infestations0/231/26
Viral infectionInfections and infestations0/231/26
Low cardiac output syndromeCardiac disorders0/231/26
Nodal arrhythmiaCardiac disorders0/231/26
Most frequent other events
Showing 10 of 17
Most frequent other events
EventPlaceboClopidogrel 0.2 mg/kg/Day
Any infections and infestationsInfections and infestations6/2314/26
Upper respiratory tract infectionInfections and infestations0/236/26
Any gastrointestinal disordersGastrointestinal disorders2/236/26
Any general disorders and administration site conditionsGeneral disorders1/236/26
PyrexiaGeneral disorders0/234/26
Any respiratory, thoracic and mediastinal disordersRespiratory, thoracic and mediastinal disorders1/234/26
PharyngitisInfections and infestations3/231/26
DiarrhoeaGastrointestinal disorders1/233/26
CoughRespiratory, thoracic and mediastinal disorders0/233/26
Any injury, poisoning and procedural complicationsInjury, poisoning and procedural complications1/233/26

Baseline characteristics

Age Continuous
Age Continuous(days)PlaceboClopidogrel 0.2 mg/kg/DayTotal
at randomization in CLARINET study45.2 ± 26.133.1 ± 20.538.8 ± 23.8
at inclusion368.1 ± 4.2368.0 ± 2.7368.0 ± 3.5
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboClopidogrel 0.2 mg/kg/DayTotal
Female101424
Male131225
Region of Enrollment
Region of Enrollment(participants)PlaceboClopidogrel 0.2 mg/kg/DayTotal
United States011
Portugal314
Taiwan459
Spain022
Russian Federation101
United Kingdom123
Italy011
India011
France011
Hungary213
Mexico6410
Brazil426
Malaysia112
Poland112
Germany033
Weight at inclusion
Weight at inclusion(kilograms (kg))PlaceboClopidogrel 0.2 mg/kg/DayTotal
Mean7.9 ± 1.18.1 ± 1.28.0 ± 1.2
Height at inclusion
Height at inclusion(centimeters (cm))PlaceboClopidogrel 0.2 mg/kg/DayTotal
Mean71.8 ± 2.870.0 ± 10.470.8 ± 7.8
Type of initial shunt palliation
Type of initial shunt palliation(participants)PlaceboClopidogrel 0.2 mg/kg/DayTotal
Modified Blalock Taussig Shunt with Norwood011
Modified Blalock Taussig Shunt without Norwood182038
Sano procedure with Norwood000
Sano procedure without Norwood112
Central shunt134
Stent of ductus arteriosus314
Shunt on cardiopulmonary bypass
Shunt on cardiopulmonary bypass(participants)PlaceboClopidogrel 0.2 mg/kg/DayTotal
Yes257
No212142
Age at shunt palliation
Age at shunt palliation(days)PlaceboClopidogrel 0.2 mg/kg/DayTotal
Mean25.7 ± 28.713.7 ± 12.719.4 ± 22.3
08

Study locations

15 sites
  • Sanofi-Aventis Administrative Office
    Bridgewater, New Jersey 08807, United States
  • Sanofi-Aventis Administrative Office
    Sao Paulo, Brazil
  • Sanofi-Aventis Administrative Office
    Paris, France
  • Sanofi-Aventis Administrative Office
    Berlin, Germany
  • Sanofi-Aventis Administrative Office
    Budapest, Hungary
  • Sanofi-Aventis Administrative Office
    Mumbai, India
  • Sanofi-Aventis Administrative Office
    Milano, Italy
  • Sanofi-Aventis Administrative Office
    Kuala Lumpur, Malaysia
  • Sanofi-Aventis Administrative Office
    Mexico, Mexico
  • Sanofi-Aventis Administrative Office
    Warszawa, Poland
  • Sanofi-Aventis Administrative Office
    Porto Salvo, Portugal
  • Sanofi-Aventis Administrative Office
    Moscow, Russian Federation
  • Sanofi-Aventis Administrative Office
    Barcelona, Spain
  • Sanofi-Aventis Administrative Office
    Taipei, Taiwan
  • Sanofi-Aventis Administrative Office
    Guildford Surrey, United Kingdom
09

References and documents

Publications

  • Avlonitis VS, Planas S, Hayes AM, Parry A. Occlusion of modified Blalock-Taussig shunt after clopidogrel cessation. Ann Thorac Surg. 2012 Feb;93(2):656-8. doi: 10.1016/j.athoracsur.2011.07.071. PubMed 22269735 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2009, a primary completion of Jul 2010 and a completion of Jul 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2011, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 29, 2009
First posted
Feb 2, 2009
Start
Jan 2009
Primary completionActual
Jul 2010
CompletionActual
Jul 2010
Results first posted
Aug 16, 2011
Last update
Aug 22, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 22, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00833703
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Feb 2, 2009
Start date
Jan 2009
Primary completion
Jul 2010
Completion
Jul 2010
Results posted
Aug 16, 2011
Last update
Aug 22, 2011

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Clopidogrel

Start the discussion